ARTICLE | Clinical News
LBR-101: Phase IIb started
January 13, 2014 8:00 AM UTC
Labrys began a double-blind, placebo-controlled Phase IIb trial to evaluate low- and high-dose subcutaneous LBR-101 once monthly for 3 months in about 270 patients with high frequency episodic migrain...